CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Major depressive disorder (MDD) is the most commonly diagnosed ... and medical communities about the difference between esketamine versus ketamine, and whether esketamine is as effective as ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
HealthDay on MSN10d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Hosted on MSN1d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Hundreds of millions of people around the world live with major depressive disorder (MDD), making it ... communities about the difference between esketamine versus ketamine, and whether esketamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback